We use cookies for a better user experience. Read our Privacy Policy
I Agree
Plantar Fasciitis Treatment Market
Plantar fasciitis has emerged as a persistent kind of repetitive strain injury that afflicts runners, hikers, and walkers, and also nearly everyone who stands for a living, such as cashiers for instance, especially on hard surfaces. The multi-factorial etiology of plantar fasciitis has led to a significant surge in the number of sufferers, while laying a firm base for the growth of companies that provide treatment for this condition. The steadily growing patient population has opened a window of opportunities for stakeholders who are widely adopting technologically-advanced products to alleviate heel pain in less period of time, and provide better relief even in worse cases. This continuing prevalence of plantar fasciitis has also paved the way for a range of customized foot orthotic insoles, specifically designed to alleviate pain while walking. With this heel pain increasing its hold on the growing geriatric population in particular, Transparency Market Research (TMR) decided to gauge the future growth prospects of the plantar fasciitis treatment market.
Identify the key factors that will drive your company’s growth. Request a brochure of this report here
There are a wide range of treatments that form a promising ally for combating severe heel pain caused by plantar fasciitis, and thereby are widening the scope of growth for stakeholders. As per TMR’s estimations, the plantar fasciitis treatment market accounted for revenue worth ~ US$ 695 Mn in 2018. A large section of the working class stands for prolonged periods of time during their jobs, and suffers from body pain, specifically ankle or foot pain, which has been found to be the predominant cause of plantar fasciitis. This can be attributed to the fact that, the manufacturing sector continues to expand at an unprecedented rate, with ~ 22% of the global population engaged in this industry, who stand at one position for a long duration. In light of the growing incidences of heel pain caused by standing for prolonged periods of time, TMR analysts envisaged that the market is highly likely to take a leap of growth, expanding 1.4X between 2018 and 2027.
Sedentary Lifestyles Shaping Market Dynamics
Though a sitting, inactive lifestyle can’t really be traced as the key cause behind plantar fasciitis, it definitely increases the risk of this condition. Moreover, the paradigm shift of individuals towards a sedentary lifestyle, coupled with their rapidly changing eating habits, has led to a significant increase in the number obesity cases. For that matter, a large part of the population has become prone to facing pressure on the joints and ankles, which can lead to plantar fasciitis. While plantar fasciitis continues to gain momentum as a common foot pain condition, an increased number of treatments are coming to the fore, with each one of them vying to suffice patient needs in a better way. As obese and geriatric populations fall close to the epicenter of plantar fasciitis, an increased number of people are falling prey to this condition.
Patient Preference for Medication Therapy in Hospitals
Hospitals accounted for over half of the revenue generated by the plantar fasciitis treatment market, finds TMR’s analysis, which further indicates that the footfall will gain momentum in the years to come. In recent years, medication therapy has garnered limelight as the most widely adopted first line of therapy to manage the symptoms associated with plantar fasciitis, such as pain and inflammation. This can be attributed to the increasing number of medical centers, hospitals, and clinics that continue to prescribe one or the other form of painkillers, such as NSAIDS or steroids, to patients to fight plantar fasciitis. It is pertinent to note that, though medication continues to maintain its position as a widely adopted treatment option, the demand for orthotics is set to grow, owing to the rise in awareness and its proven efficacy in managing plantar fasciitis.
Want to know more such detailed insights of Plantar Fasciitis Treatment Market? Request a PDF sample here
The market for plantar fasciitis treatment continues to expand at a promising pace; however, there remains several determinates as potholes in the path leading to market growth. The volatile pricing of raw materials has been compelling orthotics manufacturers to keep a stock of prerequisites such as nylon, raw leather, shoe soles, EVA foam, and carbon composites, to avoid potential interruption in manufacturing caused by the shortfall of raw materials. However, the high risk of disparity in the potential future cost of the product could diminish the profit margins of manufacturer. Moreover, the storage of raw materials also pushes the inventory turnover ratio. Furthermore, as the leather industry continues to face backlash from organizations fighting against animal cruelty, the price point of this raw material continues to spike, limiting the profit margins of stakeholders.
Strengthening Market Position through M&A
The plantar fasciitis treatment market is highly fragmented, with a large number of small players operating individually at a regional as well as global level. As market competition continues to intensify, several stakeholders have placed their focus on mergers and acquisitions to solidify their position and secure gains. For instance, in 2017, Aetrex acquired Sols System to leverage its medical and consumer-grade 3D printed orthotics as well as software for the mass customization of footwear. The same year, Superfeet Worldwide, Inc. entered into a strategic partnership with HP to create a new machine - FitStation, which was designed to create a 3D scan of a customer’s foot shape, and an analysis of the way a wearer runs or walks.
Customization in Full Swing
Orthotics made its way into the medical devices industry long back, and has managed to appeal to practitioners and patients alike. Orthotics, as a treatment for plantar fasciitis, is only preceded by medication, and is likely to emerge as a key treatment option in the coming years, as manufacturers continue to place focus on advanced and diversified offerings to move ahead of their counterparts. Manufacturers are offering custom foot orthotics (specially made shoe inserts) designed to fit perfectly on the feet. As stakeholders put microscope focus on proper foot support and comfort, the market is likely to witness an increased production of customized orthotics that are in tune with the foot structure of the patient.
A bunch of changes are underway in the market for plantar fasciitis treatment, as advanced technology continues to make inroads into every aspect of medical device manufacturing, while opening a lucrative window for the development of cost-effective variants. The effectiveness of 3D printing in reducing cost, increasing orthotic efficacy, and paving the way for innovative designs currently remains blurred in the plantar fasciitis treatment market. Though there exists minimal advantages of additive manufacturing over subtractive options for manufacturing foot orthoses on a large industrial scale, it could witness greater adoption in the years to come. This can be attributed to the fact that, several companies have placed their focus on exploiting 3D printing technology by changing existing business models and foot orthoses production processes. For instance, in 2017, Wiivv Wearables Inc. raised US$ 4 million in Series A funding for its 3D printed insoles, and also purchased a custom footbed supplier – eSoles, to set the platform for the launch of its next phase of made-to-fit footwear.
Developed regions such as North America and Europe continue to lead the plantar fasciitis treatment market, owing to the growing focus of companies on leveraging technology in manufacturing processes and subsequent launches of new orthotic-based offerings. As per TMR’s analysis, North America accounted for ~ 42% market value share in 2018, and will continue to remain a trailblazer through to 2027. This steady growth can be attributed to the high adoption of advanced treatment approaches, and growing pool of plantar fasciitis patients in the region, which is primarily driven by an increase in the geriatric and obese populations that are more susceptible to this condition. Moreover, several leading market players, including Hanger, Inc. and Pfizer, Inc., have their headquarters in North America, a fact that continues to keep the lucrativeness of the region intact.
Expanding operations in future? To get the perfect launch ask for a custom report here
Analysts’ Viewpoint
Plantar Fasciitis Could become the New Back Pain
Analysts of the report set their bets on a considerable increase in the plantar fasciitis treatment market, which is envisaged to expand at ~ 4% CAGR during 2019-2027, owing to a steady increase in foot pain incidences that are primarily driven by changing lifestyles, and growing obese and geriatric population. Companies that lay focus on streamlining their manufacturing operations of orthotics to increase their productivity are likely to witness higher growth in the years to come.
Plantar Fasciitis Treatment: Overview
Increase in the preference for orthotics such as foot insoles and splints and medication therapy drives the growth and acceptance of plantar fasciitis treatment products. Medication therapies such as acetaminophen or nonsteroidal anti-inflammatory drugs in conjunction with stretching exercises and physical therapy have been established as first line of therapy for plantar fasciitis. Cortisone injections are used to treat more severe cases.
Plantar Fasciitis Treatment Market: Novel Product Development to Boost Growth
Plantar Fasciitis Treatment Market: Increase in Sales through Online Platforms
Plantar Fasciitis Treatment Market: Rise in Demand for Custom Foot Orthotic Insoles
North America to Account for Leading Share in Global Plantar Fasciitis Treatment Market
Plantar Fasciitis Treatment Market: Companies Mentioned in Report
The report contains the profiles of leading players operating in the global plantar fasciitis treatment market. Key players operating in the plantar fasciitis treatment market include
Plantar Fasciitis Treatment Market - Segmentation
TMR’s research study gauges the plantar fasciitis treatment market based on type, end user, and region. The report sheds light on the rapidly changing market dynamics and trends related to different market segments, and how they are impacting the growth prospects of the plantar fasciitis treatment market.
|
Type |
Medication Therapy
Orthotics Shockwave Therapy
Surgery Others |
|
End User |
Hospitals Clinics Others |
|
Region |
North America Latin America Europe Asia Pacific |
Interested in this report?
Get a FREE Brochure now!
*Get Brochure Report (PDF) sent to your email within minutes
Plantar fasciitis treatment market is projected to reach ~ US$ 1 Bn by 2027
Plantar fasciitis treatment market to expand at a CAGR of ~ 4% from 2019 to 2027
Plantar fasciitis treatment market is driven by increase in the preference for orthotics
North America to account for leading share in global plantar fasciitis treatment market
North America to account for leading share in global plantar fasciitis treatment market Key players operating in the plantar fasciitis treatment market include Hanger, Inc., Bayer Group (Dr. Scholl's), A. Algeo Limited, Bauerfeind AG, Superfeet Worldwide, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Plantar Fasciitis Treatment Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Plantar Fasciitis Treatment Market Analysis and Forecast, 2017–2027
5. Market Outlook
5.1. Porter’s Five Force Analysis
5.2. Industry Evolution / Developments
5.3. Drug Pipeline for Plantar Fasciitis Treatment
5.4. Technological Advancements in Foot Orthotics/Prosthetics Industry
5.5. Price Comparison Analysis, by Product
5.6. Regulatory Scenario by Region
5.7. Compare FDM, SLA, and SLS Technologies
5.8. Obesity Rates (%) of Total Adult Population
6. Global Plantar Fasciitis Treatment Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type, 2017–2027
6.3.1. Medication Therapy
6.3.1.1. Oral
6.3.1.2. Parenteral
6.3.2. Orthotics
6.3.3. Shockwave Therapy
6.3.3.1. Extracorporeal Shock Wave Therapy (ESWT)
6.3.3.2. Intracorporeal Pneumatic Shockwave Therapy (IPST)
6.3.4. Surgery
6.3.5. Others
6.4. Market Attractiveness, by Type
7. Global Plantar Fasciitis Treatment Market Analysis and Forecast, by End User
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by End User, 2017–2027
7.3.1. Hospitals
7.3.2. Clinics
7.3.3. Others
7.4. Market Attractiveness, by End User
8. Global Plantar Fasciitis Treatment Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Country/Region
9. North America Plantar Fasciitis Treatment Market Analysis and Forecast
9.1. Introduction
9.2. Market Value Forecast, by Type, 2017–2027
9.2.1. Medication Therapy
9.2.1.1. Oral
9.2.1.2. Parenteral
9.2.2. Orthotics
9.2.3. Shockwave Therapy
9.2.3.1. Extracorporeal Shock Wave Therapy (ESWT)
9.2.3.2. Intracorporeal Pneumatic Shockwave Therapy (IPST)
9.2.4. Surgery
9.2.5. Others
9.3. Market Value Forecast, by End User, 2017–2027
9.3.1. Hospitals
9.3.2. Clinics
9.3.3. Others
9.4. Market Value Forecast, by Country, 2017–2027
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Type
9.5.2. By End User
9.5.3. By Country
10. Europe Plantar Fasciitis Treatment Market Analysis and Forecast
10.1. Introduction
10.2. Market Value Forecast, by Type, 2017–2027
10.2.1. Medication Therapy
10.2.1.1. Oral
10.2.1.2. Parenteral
10.2.2. Orthotics
10.2.3. Shockwave Therapy
10.2.3.1. Extracorporeal Shock Wave Therapy (ESWT)
10.2.3.2. Intracorporeal Pneumatic Shockwave Therapy (IPST)
10.2.4. Surgery
10.2.5. Others
10.3. Market Value Forecast, by End User, 2017–2027
10.3.1. Hospitals
10.3.2. Clinics
10.3.3. Others
10.4. Market Value Forecast, by Country/Sub-region, 2017–2027
10.4.1. U.K.
10.4.2. Germany
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Type
10.5.2. By End User
10.5.3. By Country/Sub-region
11. Asia Pacific Plantar Fasciitis Treatment Market Analysis and Forecast
11.1. Introduction
11.2. Market Value Forecast, by Type, 2017–2027
11.2.1. Medication Therapy
11.2.1.1. Oral
11.2.1.2. Parenteral
11.2.2. Orthotics
11.2.3. Shockwave Therapy
11.2.3.1. Extracorporeal Shock Wave Therapy (ESWT)
11.2.3.2. Intracorporeal Pneumatic Shockwave Therapy (IPST)
11.2.4. Surgery
11.2.5. Others
11.3. Market Value Forecast, by End User, 2017–2027
11.3.1. Hospitals
11.3.2. Clinics
11.3.3. Others
11.4. Market Value Forecast, by Country/Sub-region, 2017–2027
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. Australia
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Type
11.5.2. By End User
11.5.3. By Country/Sub-region
12. Latin America Plantar Fasciitis Treatment Market Analysis and Forecast
12.1. Introduction
12.2. Market Value Forecast, by Type, 2017–2027
12.2.1. Medication Therapy
12.2.1.1. Oral
12.2.1.2. Parenteral
12.2.2. Orthotics
12.2.3. Shockwave Therapy
12.2.3.1. Extracorporeal Shock Wave Therapy (ESWT)
12.2.3.2. Intracorporeal Pneumatic Shockwave Therapy (IPST)
12.2.4. Surgery
12.2.5. Others
12.3. Market Value Forecast, by End User, 2017–2027
12.3.1. Hospitals
12.3.2. Clinics
12.3.3. Others
12.4. Market Value Forecast, by Country/Sub-region, 2017–2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Type
12.5.2. By End User
12.5.3. By Country/Sub-region
13. Middle East & Africa Plantar Fasciitis Treatment Market Analysis and Forecast
13.1. Introduction
13.2. Market Value Forecast, by Type, 2017–2027
13.2.1. Medication Therapy
13.2.1.1. Oral
13.2.1.2. Parenteral
13.2.2. Orthotics
13.2.3. Shockwave Therapy
13.2.3.1. Extracorporeal Shock Wave Therapy (ESWT)
13.2.3.2. Intracorporeal Pneumatic Shockwave Therapy (IPST)
13.2.4. Surgery
13.2.5. Others
13.3. Market Value Forecast, by End User, 2017–2027
13.3.1. Hospitals
13.3.2. Clinics
13.3.3. Others
13.4. Market Value Forecast, by Country/Sub-region, 2017–2027
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of MEA
13.5. Market Attractiveness Analysis
13.5.1. By Type
13.5.2. By End User
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Share Analysis, by Company, 2018
14.2. Market Player - Competition Matrix (By Tier and Size of companies)
14.3. Company Profiles
14.3.1. Hanger, Inc.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Financial Overview
14.3.1.3. SWOT Analysis
14.3.1.4. Strategic Overview
14.3.2. Bayer Group (Dr. Scholl's)
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Financial Overview
14.3.2.3. SWOT Analysis
14.3.2.4. Strategic Overview
14.3.3. A. Algeo Limited
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. SWOT Analysis
14.3.3.3. Strategic Overview
14.3.4. Bauerfeind AG
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. SWOT Analysis
14.3.4.3. Strategic Overview
14.3.5. Superfeet Worldwide, Inc.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. SWOT Analysis
14.3.5.3. Strategic Overview
14.3.6. Ottobock SE & Co. KGaA (Ottobock Holding)
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. SWOT Analysis
14.3.6.3. Strategic Overview
14.3.7. Pfizer, Inc.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Financial Overview
14.3.7.3. SWOT Analysis
14.3.7.4. Strategic Overview
14.3.8. Sanofi
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Financial Overview
14.3.8.3. SWOT Analysis
14.3.8.4. Strategic Overview
14.3.9. GlaxoSmithKline plc
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Financial Overview
14.3.9.3. SWOT Analysis
14.3.9.4. Strategic Overview
List of Tables
Table 01 Drug Pipeline for Plantar Fasciitis Treatment
Table 02 Global Orthotics Market, Price Comparison Analysis, 2017
Table 03 Global Orthopedic Orthotics Market, Price Comparison Analysis, 2017
Table 04 Comparison of FDM, SLA, and SLS Technologies
Table 05 Global Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by Type, 2019–2027
Table 06 Global Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by Medication Therapy, 2019–2027
Table 07 Global Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by Shockwave Therapy, 2019–2027
Table 08 Global Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by End User, 2019–2027
Table 09 Global Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by Region, 2019–2027
Table 10 North America Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by Type, 2019–2027
Table 11 North America Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by Medication Therapy, 2019–2027
Table 12 North America Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by Shockwave Therapy, 2019–2027
Table 13 North America Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by End User, 2019–2027
Table 14 North America Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by Country, 2019–2027
Table 15 Europe Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by Type, 2019–2027
Table 16 Europe Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by Medication Therapy, 2019–2027
Table 17 Europe Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by Shockwave Therapy, 2019–2027
Table 18 Europe Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by End User, 2019–2027
Table 19 Europe Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2019–2027
Table 20 Asia Pacific Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by Type, 2019–2027
Table 21 Asia Pacific Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by Medication Therapy, 2019–2027
Table 22 Asia Pacific Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by Shockwave Therapy, 2019–2027
Table 23 Asia Pacific Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by End User, 2019–2027
Table 24 Asia Pacific Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2019–2027
Table 25 Latin America Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by Type, 2019–2027
Table 26 Latin America Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by Medication Therapy, 2019–2027
Table 27 Latin America Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by Shockwave Therapy, 2019–2027
Table 28 Latin America Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by End User, 2019–2027
Table 29 Latin America Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2019–2027
Table 30 Middle East & Africa Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by Type, 2019–2027
Table 31 Middle East & Africa Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by Medication Therapy, 2019–2027
Table 32 Middle East & Africa Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by Shockwave Therapy, 2019–2027
Table 33 Middle East & Africa Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by End User, 2019–2027
Table 34 Middle East & Africa Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2019–2027
List of Figures
Figure 01 Global Market Size (US$ Mn), by Type, 2018
Figure 02 Global Plantar Fasciitis Treatment Market Snapshot
Figure 03 Global Plantar Fasciitis Treatment Market Share, by End User, 2018
Figure 04 Market Share Analysis, by Region, 2018
Figure 05 Market Outlook, by Region
Figure 06 Global Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, 2017–2027
Figure 07 Market Value Share, by Type, 2018
Figure 08 Market Value Share, by End User, 2018
Figure 09 Market Value Share, by Region, 2018
Figure 10 Comparison between Obesity Rates of Countries, 2015
Figure 11 Global Plantar Fasciitis Treatment Market Value Share Analysis, by Type, 2018 and 2027
Figure 12 Global Plantar Fasciitis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Medication Therapy, 2017–2027
Figure 13 Global Plantar Fasciitis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Orthotics, 2017–2027
Figure 14 Global Plantar Fasciitis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Shockwave Therapy, 2017–2027
Figure 15 Global Plantar Fasciitis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Surgery, 2017–2027
Figure 16 Global Plantar Fasciitis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027
Figure 17 Global Plantar Fasciitis Treatment Market Attractiveness Analysis, by Type, 2019–2027
Figure 18 Global Plantar Fasciitis Treatment Market Value Share Analysis, by End User, 2018 and 2027
Figure 19 Global Plantar Fasciitis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2017–2027
Figure 20 Global Plantar Fasciitis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Clinics, 2017–2027
Figure 21 Global Plantar Fasciitis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027
Figure 22 Global Plantar Fasciitis Treatment Market Attractiveness Analysis, by End User, 2019–2027
Figure 23 Global Plantar Fasciitis Treatment Market Value Share Analysis, by Region, 2018 and 2027
Figure 24 Global Plantar Fasciitis Treatment Market Attractiveness Analysis, by Region, 2019–2027
Figure 25 North America Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, 2019–2027
Figure 26 North America Plantar Fasciitis Treatment Market Attractiveness Analysis, by Country, 2019–2027
Figure 27 North America Plantar Fasciitis Treatment Market Value Share Analysis, by Type, 2018 and 2027
Figure 28 North America Plantar Fasciitis Treatment Market Value Share Analysis, by End User, 2018 and 2027
Figure 29 North America Plantar Fasciitis Treatment Market Value Share Analysis, by Country, 2018 and 2027
Figure 30 North America Plantar Fasciitis Treatment Market Attractiveness Analysis, by Type, 2019–2027
Figure 31 North America Plantar Fasciitis Treatment Market Attractiveness Analysis, by End User, 2019–2027
Figure 32 Europe Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, 2019–2027
Figure 33 Europe Plantar Fasciitis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 34 Europe Plantar Fasciitis Treatment Market Value Share Analysis, by Type, 2018 and 2027
Figure 35 Europe Plantar Fasciitis Treatment Market Value Share Analysis, by End User, 2018 and 2027
Figure 36 Europe Plantar Fasciitis Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 37 Europe Plantar Fasciitis Treatment Market Attractiveness Analysis, by Type, 2019–2027
Figure 38 Europe Plantar Fasciitis Treatment Market Attractiveness Analysis, by End User, 2019–2027
Figure 39 Asia Pacific Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, 2019–2027
Figure 40 Asia Pacific Plantar Fasciitis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 41 Asia Pacific Plantar Fasciitis Treatment Market Value Share Analysis, by Type, 2018 and 2027
Figure 42 Asia Pacific Plantar Fasciitis Treatment Market Value Share Analysis, by End User, 2018 and 2027
Figure 43 Asia Pacific Plantar Fasciitis Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 44 Asia Pacific Plantar Fasciitis Treatment Market Attractiveness Analysis, by Type, 2019–2027
Figure 45 Asia Pacific Plantar Fasciitis Treatment Market Attractiveness Analysis, by End User, 2019–2027
Figure 46 Latin America Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, 2019–2027
Figure 47 Latin America Plantar Fasciitis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 48 Latin America Plantar Fasciitis Treatment Market Value Share Analysis, by Type, 2018 and 2027
Figure 49 Latin America Plantar Fasciitis Treatment Market Value Share Analysis, by End User, 2018 and 2027
Figure 50 Latin America Plantar Fasciitis Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 51 Latin America Plantar Fasciitis Treatment Market Attractiveness Analysis, by Treatment, 2019–2027
Figure 52 Latin America Plantar Fasciitis Treatment Market Attractiveness Analysis, by End User, 2019–2027
Figure 53 Middle East & Africa Plantar Fasciitis Treatment Market Size (US$ Mn) Forecast, 2019–2027
Figure 54 Middle East & Africa Plantar Fasciitis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 55 Middle East & Africa Plantar Fasciitis Treatment Market Value Share Analysis, by Type, 2018 and 2027
Figure 56 Middle East & Africa Plantar Fasciitis Treatment Market Value Share Analysis, by End User, 2018 and 2027
Figure 57 Middle East & Africa Plantar Fasciitis Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 58 Middle East & Africa Plantar Fasciitis Treatment Market Attractiveness Analysis, by Type, 2019–2027
Figure 59 Middle East & Africa Plantar Fasciitis Treatment Market Attractiveness Analysis, by End User, 2019–2027
Figure 60 Market Share Analysis (%), 2018, by Tier and Size of the Company
Figure 61 Hanger, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 62 Hanger, Inc. Operation Cost (US$ Mn) - Company Level,
Figure 63 Hanger, Inc. Material Cost (US$ Mn) - Company Level,
Figure 64 Hanger, Inc. Breakdown of Net Revenue (%), by Business Segment, 2018
Figure 65 Bayer Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 66 Bayer Breakdown of Net Sales (%), by Region/Country, 2018
Figure 67 Bayer Revenue Breakdown of Net Sales (%), by Business Segment, 2018
Figure 68 Bayer R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 69 Pfizer, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 70 Pfizer, Inc. Breakdown of Net Sales, by Region, 2018
Figure 71 Pfizer, Inc. Breakdown of Net Sales, by Business Segment (%), 2018
Figure 72 Pfizer, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 73 Sanofi Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2018
Figure 74 Sanofi Breakdown of Net Sales (%), by Region/Country, 2018
Figure 75 Sanofi Breakdown of Net Sales (%), by Operating Segment, 2018
Figure 76 Sanofi R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 77 GlaxoSmithKline plc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2018
Figure 78 GlaxoSmithKline plc. R&D Expenses and Selling, General and Administration Expenses (US$ Bn) - Company Level, 2015–2018
Figure 79 GlaxoSmithKline plc. Breakdown of Net Sales, by Region/Country (Company Level), 2018
Figure 80 GlaxoSmithKline plc. Breakdown of Net Sales, by Business Segment (Overall Company Level), 2018
Complete the form below and we'll get back to you shortly.
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
